Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genome-wide association study of plasma efavirenz pharmacokinetics in AIDS Clinical Trials Group protocols implicates several CYP2B6 variants.

Pharmacogenetics and genomics - 1 Dec 2012

Holzinger Emily R, Grady Benjamin, Ritchie Marylyn D, Ribaudo Heather J, Acosta Edward P, Morse Gene D, Gulick Roy M, Robbins Gregory K, Clifford David B, Daar Eric S, McLaren Paul, Haas David W

Abstract excerpt

OBJECTIVES: Prior candidate gene studies have associated CYP2B6 516G→T [rs3745274] and 983T→C [rs28399499] with increased plasma efavirenz exposure. We sought to identify novel variants associated with efavirenz pharmacokinetics. MATERIALS AND METHODS: Antiretroviral therapy-naive AIDS Clinical Trials Group studies A5202, A5095, and ACTG 384 included plasma sampling for efavirenz pharmacokinetics. Log-transformed...

Read the complete abstract on PubMed

Topics

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share this publication in a Topic to start or enrich a Post.

Share to Cyclopropanes
Share to Alkynes
Share to Anti-HIV Agents
Share to Aryl Hydrocarbon Hydroxylases
Share to Benzoxazines
Share to Clinical Protocols
Share to Cytochrome P-450 CYP2B6
Share to Oxidoreductases, N-Demethylating

Source

Open in PubMed Open full text

Identifiers

PMID: 23080225
DOI: 10.1097/FPC.0b013e32835a450b
PMCID: PMC3614365

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genome-wide association study of plasma efavirenz pharmacokinetics in AIDS Clinical Trials Group protocols implicates several CYP2B6 variants.PMID 23080225Read ↗

Effect of CYP2B6, ABCB1, and CYP3A5 polymorphisms on efavirenz pharmacokinetics and treatment response: an AIDS Clinical Trials Group study.Semantic proximity Read ↗

Pharmacogenetic associations with plasma efavirenz concentrations and clinical correlates in a retrospective cohort of Ghanaian HIV-infected patients.Semantic proximity Read ↗

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2B6 and Efavirenz‐Containing Antiretroviral TherapySemantic proximity Read ↗

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2B6 and Efavirenz‐Containing Antiretroviral TherapySemantic proximity Read ↗

A single-nucleotide polymorphism in CYP2B6 leads to >3-fold increases in efavirenz concentrations in plasma and hair among HIV-infected women.Semantic proximity Read ↗

Haplotype structure of CYP2B6 and association with plasma efavirenz concentrations in a Chilean HIV cohort.Semantic proximity Read ↗

Multilocus genetic interactions and response to efavirenz-containing regimens: an adult AIDS clinical trials group study.Semantic proximity Read ↗

High predictive value of CYP2B6 SNPs for steady-state plasma efavirenz levels in South African HIV/AIDS patients.Semantic proximity Read ↗

Pharmacogenetics of plasma efavirenz exposure in HIV-infected adults and children in South Africa.Semantic proximity Read ↗

Predictive value of known and novel alleles of CYP2B6 for efavirenz plasma concentrations in HIV-infected individuals.Semantic proximity Read ↗

Secondary metabolism pathway polymorphisms and plasma efavirenz concentrations in HIV-infected adults with CYP2B6 slow metabolizer genotypes.Semantic proximity Read ↗

Pharmacogenetics-based population pharmacokinetic analysis of efavirenz in HIV-1-infected individuals.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.